Information Provided By:
Fly News Breaks for February 13, 2017
IMMU, SGEN
Feb 13, 2017 | 07:41 EDT
Leerink analyst Michael Schmidt notes that Seattle Genetics (SGEN) has announced a global development and license agreement with Immunomedics (IMMU) for IMMU-132, which could potentially expand on the former's leadership position in the antibody-drug conjugate space by adding a late stage asset that has generated considerable interest based on its clinical activity seen in triple-negative breast cancer to date. The analyst reiterates an Outperform rating on Seattle Genetics' shares.
News For SGEN;IMMU From the Last 2 Days
There are no results for your query SGEN;IMMU
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.